Q32 Bio
QTTB | NASDAQ
$8.29
-$0.42 (-4.82%)
At close: Nov 16, 2026, 4:00 PM ET
$8.29
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Q32 Bio Company Profile
Company profile explainedCompany Profile
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Key Executives
| Name | Position |
|---|---|
| Jodie Pope Morrison | Chief Executive Officer & Director |
| Lee H. Kalowski | Chief Financial Officer & President |
| David Appugliese | Senior Vice President & Head of People |
| Elham Hershberger | Chief Development Officer |
| José Trevejo | Chief Medical Officer |
| Maria Marzilli | Chief Business Officer |
| Shelia Violette | Co-founder, Chief Scientific Officer & President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 14, 2026 | 4 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Oct 09, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 30, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 27, 2026 | 4 | Filing |
| Aug 27, 2026 | 4 | Filing |
| Aug 27, 2026 | 4 | Filing |
Q32 Bio
| Country | United States |
| IPO Date | Mar 28, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Jodie Pope Morrison |
Contact Details
830 Winter Street Waltham,
Massachusetts 02451 United States
Stock Details
| Ticker Symbol | QTTB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001661998 |
| CUSIP Number | 746964105 |
| ISIN Number | US7469641051 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove QTTB